showed a trendp=0.055
EUS-GE also showed a trend toward shorter time to chemotherapy resumption (17 days vs 24 days, p=0.055) and a higher probability of 6-month stent-free survival (95.5% vs 67.7%, log-rank test, p=0.047).
EUS-GE also showed a trend toward shorter time to chemotherapy resumption (17 days vs 24 days, p=0.055) and a higher probability of 6-month stent-free survival (95.5% vs 67.7%, log-rank test, p=0.047).